Khalin Dendy, MD
Internal Medicine · Bismarck, NDNPI 1659500155
Payments from drug & device makers
Across 706 payments — averaging $13.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Amgen$1K
- AstraZeneca$939
- AbbVie$881
- Boehringer Ingelheim$697
- plus $4K from 30 others
What the payments were for
- Food & beverage$9,625100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 116 | $1,232 |
| Novo Nordisk | 85 | $1,082 |
| Amgen | 71 | $1,056 |
| AstraZeneca | 19 | $939 |
| AbbVie(2 entities) | 62 | $881 |
| Boehringer Ingelheim | 64 | $697 |
| Pfizer | 68 | $597 |
| Novartis | 31 | $389 |
| Johnson & Johnson | 42 | $320 |
| Dexcom, Inc. | 15 | $259 |
| Bayer | 14 | $238 |
| Astellas Pharma US Inc | 12 | $219 |
| GSK | 22 | $212 |
| Abbott | 9 | $142 |
| Daiichi Sankyo Inc. | 7 | $128 |
| Phathom Pharmaceuticals, Inc. | 9 | $122 |
| E.r. Squibb & Sons, L.L.C. | 7 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $111 |
| Exact Sciences | 6 | $95 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $78 |
| Madrigal Pharmaceuticals | 3 | $77 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $68 |
| Axsome Therapeutics, Inc. | 3 | $64 |
| Insulet Corporation | 2 | $63 |
| Actelion Pharmaceuticals US, Inc. | 3 | $62 |
| Boston Scientific | 3 | $61 |
| Radius Health, Inc. | 3 | $60 |
| Alkermes, Inc. | 3 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Lexicon Pharmaceuticals, Inc. | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Biogen | 2 | $32 |
| Merck | 2 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Medtronic | 1 | $21 |
| Grifols USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,631 in reported general payments places this provider in the 95th percentile of 159 internal medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 292 | $367,744 |
| JardianceEmpagliflozin | 263 | $242,061 |
| EliquisApixaban | 208 | $194,849 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 81 | $74,983 |
| FarxigaDapagliflozin Propanediol | 77 | $70,881 |
| MounjaroTirzepatide | 39 | $45,926 |
| TrulicityDulaglutide | 31 | $44,851 |
| Wellbutrin XlBupropion Hcl | 16 | $33,139 |
| JanuviaSitagliptin Phosphate | 28 | $31,295 |
| RybelsusSemaglutide | 24 | $28,767 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 45 | $25,938 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $24,592 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $23,567 |
| JanumetSitagliptin Phos/Metformin Hcl | 18 | $16,607 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 55 | $15,943 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,082 | $396,510316 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $697 | $256,760280 claims |
| PfizerEliquis, Abrysvo | $597 | $210,792263 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arexvy, Shingrix | $212 | $128,760205 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,232 | $90,77770 claims |
| AstraZenecaFarxiga | $939 | $70,88177 claims |
| MerckJanuvia, Janumet | $25 | $47,90146 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $35 | $23,56719 claims |
| Johnson & JohnsonXarelto, Invokana | $320 | $19,42425 claims |
| Astellas Pharma US IncMyrbetriq | $219 | $5,97712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 159 internal medicine providers in North Dakota.
Other internal medicine in Bismarck
- Stephanie CanhamBismarck$4K
- Radu RautaBismarck$3K
- Donald GrenzBismarck$3K
- Julia SchwartzBismarck$3K
- Amanda BlanchardBismarck$3K
- Anita MehtaBismarck$1K
- Ramtin RamseyBismarck$958
- Michael LuckenbillBismarck$910
- Sean AllojuBismarck$843
- Khris RamdeenBismarck$612
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.